Table 1.
Clinicopathologic characteristics of the 672 patients with metastatic nasopharyngeal carcinoma (NPC)
| Characteristic | Total (cases) | Deaths [cases (%)] | Unadjusted HR (95 % CI) | P value |
|---|---|---|---|---|
| Total | 672 | 458 | ||
| Gender | ||||
| Male | 546 | 371 (67.9) | Reference | 0.700 |
| Female | 126 | 87 (69.0) | 1.05 (0.83, 1.32) | |
| Age (years) | ||||
| <46 | 316 | 213 (67.4) | Reference | 0.124 |
| ≥46 | 356 | 245 (68.8) | 1.16 (0.96, 1.39) | |
| T stage* | ||||
| T1-2 | 273 | 184 (67.4) | Reference | 0.975 |
| T3-4 | 399 | 274 (68.7) | 1.00 (0.83, 1.20) | |
| N stage* | ||||
| N0-1 | 273 | 172 (63.0) | Reference | <0.001 |
| N2-3 | 399 | 286 (71.7) | 1.42 (1.18, 1.72) | |
| Metastasis at presentation | ||||
| Absent | 375 | 261 (69.6) | Reference | 0.825 |
| Present | 297 | 197 (66.3) | 0.98 (0.81, 1.18) | |
| Number of metastatic lesions | ||||
| 1 | 105 | 51 (48.6) | Reference | <0.001 |
| ≥2 | 567 | 407 (71.8) | 2.06 (1.54, 2.77) | |
| Bone metastasis | ||||
| Absent | 280 | 196 (70.0) | Reference | 0.862 |
| Present | 392 | 262 (66.8) | 1.02 (0.85, 1.22) | |
| Liver metastasis | ||||
| Absent | 443 | 283 (63.9) | Reference | <0.001 |
| Present | 229 | 175 (76.4) | 1.62 (1.34, 1,95) | |
| Lung metastasis | ||||
| Absent | 462 | 309 (66.9) | Reference | 0.847 |
| Present | 210 | 149 (71.0) | 0.98 (0.81, 1.19) | |
| Extraregional lymph node metastasis | ||||
| Absent | 497 | 328 (66.0) | Reference | 0.060 |
| Present | 175 | 130 (74.3) | 1.22 (0.99, 1.49) | |
| EBV VCA/IgA | ||||
| <1:80 | 80 | 48 (60.0) | Reference | 0.413 |
| 1:80–1:320 | 395 | 270 (68.4) | 1.15 (0.84, 1.56) | |
| ≥1:640 | 197 | 140 (71.1) | 1.17 (0.85, 1.63) | |
| EBV EA/IgA | ||||
| <1:10 | 128 | 84 (65.6) | Reference | 0.385 |
| 1:10–1:20 | 216 | 149 (69.0) | 0.97 (0.74, 1.27) | |
| ≥1:40 | 328 | 225 (68.6) | 0.91 (0.71, 1.16) | |
| Lymphocyte count (× 109/L) | ||||
| <1.390 | 340 | 250 (73.5) | Reference | 0.002 |
| ≥1.390 | 332 | 208 (62.7) | 0.75 (0.63, 0.90) | |
| Monocyte count (× 109/L) | ||||
| <0.665 | 428 | 263 (61.4) | Reference | <0.001 |
| ≥0.665 | 244 | 195 (80.0) | 2.17 (1.80,2.62) | |
| LMR | ||||
| <2.475 | 335 | 269 (80.3) | Reference | <0.001 |
| ≥2.475 | 337 | 189 (56.1) | 0.45 (0.37, 0.54) |
HR, hazard ratio; CI, confidence interval; EBV, Epstein-Barr virus; VCA/IgA, immunoglobulin A against viral capsid antigen; EA/IgA, immunoglobulin A against early antigen; LMR, lymphocyte-to-monocyte ratio. *The American Joint Committee on Cancer (AJCC) 2002 system was used for staging at the diagnosis of NPC